Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma

Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma

Vikas A Gupta, Ajay K Nooka, Sagar Lonial, Lawrence H BoiseDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USAAbstract: Treatment of refractory and/or relapsed multiple myeloma has been a challenging problem for over 20 years...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gupta VA, Nooka AK, Lonial S, Boise LH
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Diseases of the blood and blood-forming organs
RC633-647.5
Acceso en línea:https://doaj.org/article/d4e75dca93aa4addb989dbed6c00bdd2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d4e75dca93aa4addb989dbed6c00bdd2
record_format dspace
spelling oai:doaj.org-article:d4e75dca93aa4addb989dbed6c00bdd22021-12-02T02:49:56ZClinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma1179-9889https://doaj.org/article/d4e75dca93aa4addb989dbed6c00bdd22013-05-01T00:00:00Zhttp://www.dovepress.com/clinical-potential-of-carfilzomib-in-the-treatment-of-relapsed-and-ref-a13078https://doaj.org/toc/1179-9889Vikas A Gupta, Ajay K Nooka, Sagar Lonial, Lawrence H BoiseDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USAAbstract: Treatment of refractory and/or relapsed multiple myeloma has been a challenging problem for over 20 years. However, we have made significant progress addressing this disease with the use of bortezomib, the first in class proteasome inhibitor, and the immunomodulatory agents, thalidomide and lenalidomide. Carfilzomib, the second-generation proteasome inhibitor, has also been approved for treatment of relapsed/refractory multiple myeloma. Carfilzomib is a highly selective and potent inhibitor of proteasome chymotrypsin-like activity. Phase I and II clinical trials have reported an acceptable toxicity profile, with manageable thrombocytopenia and anemia being the most common side effects. Peripheral neuropathy, a frequent dose-limiting side effect of bortezomib, was rare. Further, carfilzomib demonstrated encouraging single-agent activity and appeared to be effective even in patients refractory to bortezomib. Based on these promising data, carfilzomib is moving forward into Phase III trials for relapsed multiple myeloma and is also being investigated as front-line combination therapy for patients with newly diagnosed myeloma.Keywords: proteasome inhibitor, bortezomib, pharmacology, safety, efficacyGupta VANooka AKLonial SBoise LHDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2013, Iss default, Pp 41-51 (2013)
institution DOAJ
collection DOAJ
language EN
topic Diseases of the blood and blood-forming organs
RC633-647.5
spellingShingle Diseases of the blood and blood-forming organs
RC633-647.5
Gupta VA
Nooka AK
Lonial S
Boise LH
Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
description Vikas A Gupta, Ajay K Nooka, Sagar Lonial, Lawrence H BoiseDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USAAbstract: Treatment of refractory and/or relapsed multiple myeloma has been a challenging problem for over 20 years. However, we have made significant progress addressing this disease with the use of bortezomib, the first in class proteasome inhibitor, and the immunomodulatory agents, thalidomide and lenalidomide. Carfilzomib, the second-generation proteasome inhibitor, has also been approved for treatment of relapsed/refractory multiple myeloma. Carfilzomib is a highly selective and potent inhibitor of proteasome chymotrypsin-like activity. Phase I and II clinical trials have reported an acceptable toxicity profile, with manageable thrombocytopenia and anemia being the most common side effects. Peripheral neuropathy, a frequent dose-limiting side effect of bortezomib, was rare. Further, carfilzomib demonstrated encouraging single-agent activity and appeared to be effective even in patients refractory to bortezomib. Based on these promising data, carfilzomib is moving forward into Phase III trials for relapsed multiple myeloma and is also being investigated as front-line combination therapy for patients with newly diagnosed myeloma.Keywords: proteasome inhibitor, bortezomib, pharmacology, safety, efficacy
format article
author Gupta VA
Nooka AK
Lonial S
Boise LH
author_facet Gupta VA
Nooka AK
Lonial S
Boise LH
author_sort Gupta VA
title Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
title_short Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
title_full Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
title_fullStr Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
title_full_unstemmed Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
title_sort clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
publisher Dove Medical Press
publishDate 2013
url https://doaj.org/article/d4e75dca93aa4addb989dbed6c00bdd2
work_keys_str_mv AT guptava clinicalpotentialofcarfilzomibinthetreatmentofrelapsedandrefractorymultiplemyeloma
AT nookaak clinicalpotentialofcarfilzomibinthetreatmentofrelapsedandrefractorymultiplemyeloma
AT lonials clinicalpotentialofcarfilzomibinthetreatmentofrelapsedandrefractorymultiplemyeloma
AT boiselh clinicalpotentialofcarfilzomibinthetreatmentofrelapsedandrefractorymultiplemyeloma
_version_ 1718402129546182656

Ejemplares similares